Clinical Trial Update: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Olomorasib (LY3537982) in combination with standard of care for KRAS G12C-mutant non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Olomorasib (olomorasib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: RECRUITING